Improving the transport of chemotherapeutic drugs across the blood-brain barrier

Expert Review of Clinical Pharmacology

Volumn 4, Issue 4, 2011, Pages 477-490

  Orthmann, Andrea ^a   Fichtner, Iduna ^a   Zeisig, Reiner ^a  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

blood brain barrier; brain cancer; liposomes; nanoparticle; targeting

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANG 1005; ANG 1007; ANG 1009; ANTINEOPLASTIC AGENT; CYCLOSPORIN A; DAUNORUBICIN; DIAMORPHINE; DOCETAXEL; DOXORUBICIN; FUROCOUMARIN DERIVATIVE; IRINOTECAN; LANIQUIDAR; LEVODOPA; LOBRADIMIL; MORPHINE; PACLITAXEL; PALIPERIDONE; PROCYANIDIN; RISPERIDONE; TAMOXIFEN; TARIQUIDAR; TAXANE DERIVATIVE; TEMOZOLOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL; VINCRISTINE; ZIDOVUDINE; ZOSUQUIDAR;

ACOUSTICS; ACTIVE TRANSPORT; BLOOD BRAIN BARRIER; BRAIN CANCER; BRAIN CAPILLARY; BRAIN METASTASIS; CANCER SURVIVAL; CHEMICAL MODIFICATION; CONTRAST ENHANCEMENT; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG EFFICACY; DRUG FORMULATION; DRUG METABOLISM; DRUG PENETRATION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TARGETING; DRUG TRANSPORT; EMULSION; ENCAPSULATION; ENDOCYTOSIS; FIBROBLAST; HUMAN; IMMUNOGENICITY; INHIBITION KINETICS; LIGAND BINDING; LIPOPHILICITY; LIPOSOMAL DELIVERY; MACROPHAGE; MALIGNANT NEOPLASTIC DISEASE; MICELLE; MYCOSIS; NANOMEDICINE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PASSIVE TRANSPORT; PLASMID; RADIATION; REVIEW; TIGHT JUNCTION; TRANSCYTOSIS; TUMOR MICROENVIRONMENT; ULTRASOUND; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; DRUG CARRIERS; HUMANS; LIPOSOMES;

EID: 79960422137     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/ecp.11.26     Document Type: Review

References (162)

1. Krebs in Deutschland 2005/2006, Häufigkeit und Trends. 7. Auflage, Robert-Koch Institut (2010).
2. Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY, Olson JJ. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J. Clin. 60, 166-193 (2010).
3. Pardridge WM. Biopharmaceutical drug targeting to the brain. J. Drug Target. 18, 157-167 (2010).
4. Ecker GF, Noe CR. In silico prediction models for blood-brain barrier permeation. Curr. Med. Chem. 11, 1617-1628 (2004). (Pubitemid 38735798)
5. Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ. Structure and function of the blood-brain barrier. Neurobiol. Dis. 37, 13-25 (2010).
6. Bhaskar S, Tian F, Stoeger T et al. Multifunctional Nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: perspectives on tracking and neuroimaging. Part. Fibre Toxicol. 7, 1-25 (2010).
7. Rubin LL, Staddon JM. The cell biology of the blood-brain barrier. Annu. Rev. Neurosci. 22, 11-28 (1999). (Pubitemid 29144879)
8. Citi S, Cordenonsi M. Tight junction proteins. Biochim. Biophys. Acta 19, 1448, 1-11 (1998). (Pubitemid 28526614)
9. Goldstein GW, Betz AL. Recent advances in understanding brain capillary function. Ann. Neurol. 14, 389-395 (1983). (Pubitemid 13010038)
10. Herz J, Strickland DK. LRP: a multifunctional scavenger and signaling receptor. J. Clin. Invest. 108, 779-784 (2001). (Pubitemid 32880284)
11. Moos T, Morgan EH. Transferrin and transferrin receptor function in brain barrier systems. Cell Mol. Neurobiol. 20, 77-95 (2000). (Pubitemid 30090917)
12. Biessels GJ, Bravenboer B, Gispen WH. Glucose, insulin and the brain. modulation of cognition and synaptic plasticity in health and disease: a preface. Eur. J. Pharmacol. 490, 1-4 (2004). (Pubitemid 38482156)
13. Bjorbaek C, Elmquist JK, Michl P et al. Expression of leptin receptor isoforms in rat brain microvessels. Endocrinology 139, 3485-3491 (1998). (Pubitemid 28512305)
14. Duffy KR, Pardridge WM, Rosenfeld RG. Human blood-brain barrier insulin-like growth factor receptor. Metabolism 37, 136-140 (1988). (Pubitemid 18055228)
15. Miller G. Drug targeting. Breaking down barriers. Science 297, 1116-1118 (2002). (Pubitemid 36193322)
16. Engelhardt B, Sorokin L. The blood-brain and the blood-cerebrospinal fluid barriers: function and dysfunction. Semin. Immunopathol. 31, 497-511 (2009).
17. Zhang W, Mojsilovic-Petrovic J, Andrade MF, Zhang H, Ball M, Stanimirovic DB. The expression and functional characterization of ABCG2 in brain endothelial cells and vessels. FASEB J. 17, 2085-2087 (2003).
18. Ueno M, Nakagawa T, Wu B et al. Transporters in the brain endothelial barrier. Curr. Med. Chem. 17, 1125-1138 (2010).
19. Girardin F. Membrane transporter proteins. a challenge for CNS drug development. Dialogues Clin. Neurosci. 8, 311-321 (2006). (Pubitemid 44682748)
20. Loscher W, Potschka H. Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx 2, 86-98 (2005). (Pubitemid 40128029)
21. Loscher W, Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat. Rev. Neurosci. 6, 591-602 (2005). (Pubitemid 41059334)
22. Ghose AK, Viswanadhan VN, Wendoloski JJ. A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. J. Comb. Chem. 1, 55-68 (1999).
23. Kumagai AK, Eisenberg JB, Pardridge WM. Absorptive-mediated endocytosis of cationized albumin and a b-endorphin-cationized albumin chimeric peptide by isolated brain capillaries. Model system of blood-brain barrier transport. J. Biol. Chem. 262, 15214-15219 (1987). (Pubitemid 17160184)
24. Pardridge WM, Triguero D, Buciak J. Transport of histone through the blood-brain barrier. J. Pharmacol. Exp. Ther. 251, 821-826 (1989). (Pubitemid 20024891)
25. Betz AL, Bowman PD, Goldstein GW. Hexose transport in microvascular endothelial cells cultured from bovine retina. Exp. Eye Res. 36, 269-277 (1983). (Pubitemid 13144999)
26. Farrell CL, Pardridge WM. Blood-brain barrier glucose transporter is asymmetrically distributed on brain capillary endothelial lumenal and ablumenal membranes: an electron microscopic immunogold study. Proc. Natl Acad. Sci. USA 88, 5779-5783 (1991). (Pubitemid 21914829)
27. Pardridge WM, Oldendorf WH. Kinetic analysis of blood-brain barrier transport of amino acids. Biochim. Biophys. Acta. 401, 128-136 (1975).
28. Cancilla PA, DeBault LE. Neutral amino acid transport properties of cerebral endothelial cells in vitro. J. Neuropathol. Exp. Neurol. 42, 191-199 (1983). (Pubitemid 13114129)
29. Mann GE, Yudilevich DL, Sobrevia L. Regulation of amino acid and glucose transporters in endothelial and smooth muscle cells. Physiol. Rev. 83, 183-252 (2003). (Pubitemid 36459881)
30. Ciechanover A. Proteolysis. from the lysosome to ubiquitin and the proteasome. Nat. Rev. Mol. Cell Biol. 6, 79-87 (2005).
31. Fenstermacher J, Kaye T. Drug 'diffusion' within the brain. Ann. NY Acad. Sci. 531, 29-39 (1988).
32. Liu X, Chen C. Strategies to optimize brain penetration in drug discovery. Curr. Opin. Drug Discov. Devel. 8, 505-512 (2005). (Pubitemid 40917412)
33. Stamatovic SM, Keep RF, Andjelkovic AV. Brain endothelial cell-cell junctions: how to 'open' the blood brain barrier. Curr. Neuropharmacol. 6, 179-192 (2008).
34. Kemper EM, Boogerd W, Thuis I, Beijnen JH, van TO. Modulation of the blood-brain barrier in oncology: therapeutic opportunities for the treatment of brain tumors? Cancer Treat. Rev. 30, 415-423 (2004). (Pubitemid 38968122)
35. Packer RJ, Krailo M, Mehta M et al. A Phase I study of concurrent RMP-7 and carboplatin with radiation therapy for children with newly diagnosed brainstem gliomas. Cancer 104, 1968-1974 (2005). (Pubitemid 41513182)
36. Warren K, Jakacki R, Widemann B et al. Phase II trial of intravenous lobradimil and carboplatin in childhood brain tumors: a report from the Children's Oncology Group. Cancer Chemother. Pharmacol. 58, 343-347 (2006). (Pubitemid 43800737)
37. van VM, Kal HB, Taphoorn MJ, El-Sharouni SY. Changes in blood-brain barrier permeability induced by radiotherapy: implications for timing of chemotherapy? (Review). Oncol. Rep. 9, 683-688 (2002).
38. Jalali S, Huang Y, Dumont DJ, Hynynen K. Focused ultrasound-mediated BBB disruption is associated with an increase in activation of AKT: experimental study in rats. BMC Neurol. 10, 114-114 (2010).
39. O'Reilly MA, Waspe AC, Ganguly M, Hynynen K. Focused-ultrasound disruption of the blood-brain barrier using closely-timed short pulses: influence of sonication parameters and injection rate. Ultrasound Med. Biol. 37, 587-594 (2011).
40. Huang Y, Hynynen K. MR-guided focused ultrasound for brain ablation and blood-brain barrier disruption. Methods Mol. Biol. 711, 579-593 (2011).
41. Scherrmann JM. Drug delivery to brain via the blood-brain barrier. Vascul. Pharmacol. 38, 349-354 (2002).
42. Decleves X, Amiel A, Delattre JY, Scherrmann JM. Role of ABC transporters in the chemoresistance of human gliomas. Curr. Cancer Drug Targets 6, 433-445 (2006). (Pubitemid 44033391)
43. Ueno M, Nakagawa T, Wu B et al. Transporters in the brain endothelial barrier. Curr. Med. Chem. 17, 1125-1138 (2010).
44. Kuntner C, Bankstahl JP, Bankstahl M et al. Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[(11)C]verapamil PET. Eur. J. Nucl. Med. Mol. Imaging 37, 942-953 (2010).
45. Colabufo NA, Berardi F, Perrone MG et al. Substrates, inhibitors and activators of P-glycoprotein: candidates for radiolabeling and imaging perspectives. Curr. Top. Med. Chem. 10, 1703-1714 (2010).
46. He L, Zhao C, Yan M, Zhang LY, Xia YZ. Inhibition of P-glycoprotein function by procyanidine on blood-brain barrier. Phytother. Res. 23, 933-937 (2009).
47. Adams M, Mahringer A, Bauer R, Fricker G, Efferth T. In vitro cytotoxicity and P-glycoprotein modulating effects of geranylated furocoumarins from Tetradium daniellii. Planta Med. 73, 1475-1478 (2007). (Pubitemid 350240505)
48. Zhu HJ, Wang JS, Markowitz JS, Donovan JL, Gibson BB, DeVane CL. Risperidone and paliperidone inhibit p-glycoprotein activity in vitro. Neuropsychopharmacology 32, 757-764 (2007). (Pubitemid 46426181)
49. Di L, Kerns EH, Bezar IF, Petusky SL, Huang Y. Comparison of blood-brain barrier permeability assays: in situ brain perfusion, MDR1-MDCKII and PAMPA-BBB. J. Pharm. Sci. 98, 1980-1991 (2009).
50. Oldendorf WH, Hyman S, Braun L, Oldendorf SZ. Blood-brain barrier: penetration of morphine, codeine, heroin, and methadone after carotid injection. Science 178, 984-986 (1972).
51. Kageyama T, Nakamura M, Matsuo A et al. The 4F2hc/LAT1 complex transports L-DOPA across the blood-brain barrier. Brain Res. 879, 115-121 (2000).
52. Vorbrodt AW. Ultracytochemical characterization of anionic sites in the wall of brain capillaries. J. Neurocytol. 18, 359-368 (1989). (Pubitemid 19147403)
53. Zorko M, Langel U. Cell-penetrating peptides: mechanism and kinetics of cargo delivery. Adv. Drug Deliv. Rev. 57, 529-545 (2005). (Pubitemid 40255559)
54. Saar K, Lindgren M, Hansen M et al. Cell-penetrating peptides: a comparative membrane toxicity study. Anal. Biochem. 345, 55-65 (2005). (Pubitemid 41558194)
55. Im J, Kim W, Kim KT, Chung SK. Preparation of a 3́-azido-3́- deoxythymidine (AZT) derivative, which is blood-brain barrier permeable. Chem. Commun. 4669-4671 (2009).
56. Boado RJ. Blood-brain barrier transport of non-viral gene and RNAi therapeutics. Pharm. Res. 24, 1772-1787 (2007). (Pubitemid 47206622)
57. Ying X, Wen H, Yao HJ et al. Pharmacokinetics and tissue distribution of dual-targeting daunorubicin liposomes in mice. Pharmacology 87, 105-114 (2011).
58. Markoutsa E, Pampalakis G, Niarakis A et al. Uptake and permeability studies of BBB-targeting immunoliposomes using the hCMEC/D3 cell line. Eur. J. Pharm. Biopharm. 77, 265-274 (2011).
59. Ko YT, Bhattacharya R, Bickel U. Liposome encapsulated polyethylenimine/ODN polyplexes for brain targeting. J. Control. Release 133, 230-237 (2009).
60. Pardridge WM. Preparation of Trojan horse liposomes (THLs) for gene transfer across the blood-brain barrier. Cold Spring Harb. Protoc. DOI: 10.1101/pdb.prot5407 (2010) (Epub ahead of print).
61. Wang YY, Lui PC, Li JY. Receptor-mediated therapeutic transport across the blood-brain barrier. Immunotherapy 1, 983-993 (2009).
62. Ulbrich K, Knobloch T, Kreuter J. Targeting the insulin receptor: nanoparticles for drug delivery across the blood-brain barrier (BBB). J. Drug Target. 19, 125-132 (2011).
63. Pardridge WM. Molecular biology of the blood-brain barrier. Mol. Biotechnol. 30, 57-70 (2005).
64. Boado RJ, Hui EK, Lu JZ, Pardridge WM. Drug targeting of erythropoietin across the primate blood-brain barrier with an IgG molecular Trojan horse. J. Pharmacol. Exp. Ther. 333, 961-969 (2010).
65. Demeule M, Regina A, Che C et al. Identification and design of peptides as a new drug delivery system for the brain. J. Pharmacol. Exp. Ther. 324, 1064-1072 (2008). (Pubitemid 351397849)
66. Mousazadeh M, Palizban A, Salehi R, Salehi M. Gene delivery to brain cells with apoprotein E derived peptide conjugated to polylysine (apoEdp-PLL). J. Drug Target. 15, 226-230 (2007). (Pubitemid 46562635)
67. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 232, 34-47 (1986). (Pubitemid 16037973)
68. Herz J, Hamann U, Rogne S, Myklebost O, Gausepohl H, Stanley KK. Surface location and high affinity for calcium of a 500-kd liver membrane protein closely related to the LDL-receptor suggest a physiological role as lipoprotein receptor. EMBO J. 7, 4119-4127 (1988).
69. Strickland DK, Gonias SL, Argraves WS. Diverse roles for the LDL receptor family. Trends Endocrinol. Metab. 13, 66-74 (2002). (Pubitemid 36740449)
70. Raychowdhury R, Niles JL, McCluskey RT, Smith JA. Autoimmune target in Heymann nephritis is a glycoprotein with homology to the LDL receptor. Science 244, 1163-1165 (1989). (Pubitemid 19170485)
71. Takahashi S, Kawarabayasi Y, Nakai T, Sakai J, Yamamoto T. Rabbit very low density lipoprotein receptor: a low density lipoprotein receptor-like protein with distinct ligand specificity. Proc. Natl Acad. Sci. USA 89, 9252-9256 (1992).
72. Kim DH, Iijima H, Goto K et al. Human apolipoprotein E receptor 2. A novel lipoprotein receptor of the low density lipoprotein receptor family predominantly expressed in brain. J. Biol. Chem. 271, 8373-8380 (1996).
73. Lillis AP, Van Duyn LB, Murphy-Ullrich JE, Strickland DK. LDL receptor-related protein 1, unique tissue-specific functions revealed by selective gene knockout studies. Physiol. Rev. 88, 887-918 (2008).
74. Andersen OM, Christensen PA, Christensen LL et al. Specific binding of a-macroglobulin to complement-type repeat CR4 of the low-density lipoprotein receptor-related protein. Biochemistry 39, 10627-10633 (2000).
75. Yepes M, Sandkvist M, Moore EG et al. Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. J. Clin. Invest. 112, 1533-1540 (2003). (Pubitemid 38056279)
76. Demeule M, Currie JC, Bertrand Y et al. Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector angiopep-2. J. Neurochem. 106, 1534-1544 (2008).
77. Thomas FC, Taskar K, Rudraraju V et al. Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer. Pharm. Res. 26, 2486-2494 (2009).
78. Che C, Yang G, Thiot C et al. New Angiopep-modified doxorubicin (ANG1007) and etoposide (ANG1009) chemotherapeutics with increased brain penetration. J. Med. Chem. 53, 2814-2824 (2010).
79. Liu Y, Li J, Shao K et al. A leptin derived 30-amino-acid peptide modified pegylated poly-l-lysine dendrigraft for brain targeted gene delivery. Biomaterials 31, 5246-5257 (2010).
80. Urayama A, Grubb JH, Sly WS, WA. Mannose 6-phosphate receptor-mediated transport of sulfamidase across the blood-brain barrier in the newborn mouse. Mol. Ther. 16, 1261-1266 (2008). (Pubitemid 351866057)
81. Wu D, Pardridge WM. Blood-brain barrier transport of reduced folic acid. Pharm. Res. 16, 415-419 (1999). (Pubitemid 29162100)
82. Qin J, Chen D, Lu W et al. Preparation, characterization, and evaluation of liposomal ferulic acid in vitro and in vivo. Drug Dev. Ind. Pharm. 34, 602-608 (2008). (Pubitemid 351878677)
83. Agarwal A, Lariya N, Saraogi G, Dubey N, Agrawal H, Agrawal GP. Nanoparticles as novel carrier for brain delivery: a review. Curr. Pharm. Des. 15, 917-925 (2009).
84. Blasi P, Schoubben A, Giovagnoli S, Rossi C, Ricci M. Lipid nanoparticles for drug delivery to the brain: in vivo veritas. J. Biomed. Nanotechnol. 5, 344-350 (2009).
85. Patel MM, Goyal BR, Bhadada SV, Bhatt JS, Amin AF. Getting into the brain: approaches to enhance brain drug delivery. CNS Drugs 23, 35-58 (2009).
86. Tiwari SB, Amiji MM. A review of nanocarrier-based CNS delivery systems. Curr. Drug Deliv. 3, 219-232 (2006). (Pubitemid 43738987)
87. Bartsch M, Weeke-Klimp AH, Meijer DK, Scherphof GL, Kamps JA. Cell-specific targeting of lipid-based carriers for ODN and DNA. J. Liposome Res. 15, 59-92 (2005). (Pubitemid 40976307)
88. De Jong WH, Borm PJ. Drug delivery and nanoparticles:applications and hazards. Int. J. Nanomedicine 3, 133-149 (2008).
89. Bruchez M Jr, Moronne M, Gin P, Weiss S, Alivisatos AP. Semiconductor nanocrystals as fluorescent biological labels. Science 281, 2013-2016 (1998). (Pubitemid 28475485)
90. Chan WC, Nie S. Quantum dot bioconjugates for ultrasensitive nonisotopic detection. Science 281, 2016-2018 (1998). (Pubitemid 28475486)
91. Cui D, Tian F, Coyer SR et al. Effects of antisense-myc-conjugated single-walled carbon nanotubes on HL-60 cells. J. Nanosci. Nanotechnol. 7, 1639-1646 (2007).
92. Edelstein RL, Tamanaha CR, Sheehan PE et al. The BARC biosensor applied to the detection of biological warfare agents. Biosens. Bioelectron. 14, 805-813 (2000). (Pubitemid 30055361)
93. Nam JM, Thaxton CS, Mirkin CA. Nanoparticle-based bio-bar codes for the ultrasensitive detection of proteins. Science 301, 1884-1886 (2003). (Pubitemid 37221389)
94. Zheng J, Constantinou PE, Micheel C, Alivisatos AP, Kiehl RA, Seeman NC. Two-dimensional nanoparticle arrays show the organizational power of robust DNA motifs. Nano Lett. 6, 1502-1504 (2006). (Pubitemid 44195336)
95. Rodriguez-Carmona E, Villaverde A. Nanostructured bacterial materials for innovative medicines. Trends Microbiol. 18, 423-430 (2010).
96. Yang H. Nanoparticle-mediated brain-specific drug delivery, imaging, and diagnosis. Pharm. Res. 27, 1759-1771 (2010).
97. Olivier JC. Drug transport to brain with targeted nanoparticles. NeuroRx 2, 108-119 (2005).
98. Singh R, Lillard JW Jr. Nanoparticle-based targeted drug delivery. Exp. Mol. Pathol. 86, 215-223 (2009).
99. Win KY, Feng SS. In vitro and in vivo studies on vitamin E TPGS-emulsified poly(d, l-lactic-co-glycolic acid) nanoparticles for paclitaxel formulation. Biomaterials 27, 2285-2291 (2006). (Pubitemid 41774539)
100. Krewson CE, Klarman ML, Saltzman WM. Distribution of nerve growth factor following direct delivery to brain interstitium. Brain Res. 680, 196-206 (1995).
101. Lu W, Wan J, She Z, Jiang X. Brain delivery property and accelerated blood clearance of cationic albumin conjugated pegylated nanoparticle. J. Control. Release 118, 38-53 (2007). (Pubitemid 46283096)
102. Pardridge WM. Drug targeting to the brain. Pharm. Res. 24, 1733-1744 (2007). (Pubitemid 47206623)
103. Kreuter J. Influence of the surface properties on nanoparticle-mediated transport of drugs to the brain. J. Nanosci. Nanotechnol. 4, 484-488 (2004). (Pubitemid 39387399)
104. Rempe R, Cramer S, Huwel S, Galla HJ. Transport of poly(n-butylcyano- acrylate) nanoparticles across the blood-brain barrier in vitro and their influence on barrier integrity. Biochem. Biophys. Res. Commun. 406, 64-69 (2011).
105. Gelperina S, Maksimenko O, Khalansky A et al. Drug delivery to the brain using surfactant-coated poly(lactide-co-glycolide) nanoparticles: influence of the formulation parameters. Eur. J. Pharm. Biopharm. 74, 157-163 (2010).
106. Schroeder U, Sommerfeld P, Ulrich S, Sabel BA. Nanoparticle technology for delivery of drugs across the blood-brain barrier. J. Pharm. Sci. 87, 1305-1307 (1998). (Pubitemid 28514132)
107. Kreuter J, Shamenkov D, Petrov V et al. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J. Drug Target. 10, 317-325 (2002). (Pubitemid 34746313)
108. Friese A, Seiller E, Quack G, Lorenz B, Kreuter J. Increase of the duration of the anticonvulsive activity of a novel NMDA receptor antagonist using poly(butylcyanoacrylate) nanoparticles as a parenteral controlled release system. Eur. J. Pharm. Biopharm. 49, 103-109 (2000). (Pubitemid 30126057)
109. Alyautdin RN, Tezikov EB, Ramge P, Kharkevich DA, Begley DJ, Kreuter J. Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate 80-coated polybutylcyanoacrylate nanoparticles: an in situ brain perfusion study. J. Microencapsul. 15, 67-74 (1998). (Pubitemid 28031791)
110. Wilson B, Samanta MK, Santhi K et al. Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease. Brain Res. 20, 159-168 (2008).
111. Shubar HM, Lachenmaier S, Heimesaat MM et al. SDS-coated atovaquone nanosuspensions show improved therapeutic efficacy against experimental acquired and reactivated toxoplasmosis by improving passage of gastrointestinal and blood-brain barriers. J. Drug Target. 19, 114-124 (2011).
112. Price TO, Farr SA, Yi X et al. Transport across the blood-brain barrier of pluronic leptin. Pharmacol. Exp. Ther. 333, 253-263 (2010).
113. Kreuter J, Gelperina S. Use of nanoparticles for cerebral cancer. Tumori. 94, 271-277 (2008). (Pubitemid 351838835)
114. Etrych T, Sirova M, Starovoytova L, Rihova B, Ulbrich K. HPMA copolymer conjugates of paclitaxel and docetaxel with pH-controlled drug release. Mol. Pharmacol. 7, 1015-1026 (2010).
115. Blasi P, Giovagnoli S, Schoubben A, Ricci M, Rossi C. Solid lipid nanoparticles for targeted brain drug delivery. Adv. Drug Deliv. Rev. 59, 454-477 (2007). (Pubitemid 47259226)
116. Joshi MD, Muller RH. Lipid nanoparticles for parenteral delivery of actives. Eur. J. Pharm. Biopharm. 71, 161-172 (2009).
117. Olbrich C, Gessner A, Kayser O, Muller RH. Lipid-drug-conjugate (LDC) nanoparticles as novel carrier system for the hydrophilic antitrypanosomal drug diminazenediaceturate. J. Drug Target. 10, 387-396 (2002).
118. Date AA, Joshi MD, Patravale VB. Parasitic diseases: liposomes and polymeric nanoparticles versus lipid nanoparticles. Adv. Drug Deliv. Rev. 59, 505-521 (2007). (Pubitemid 47259228)
119. Wong HL, Bendayan R, Rauth AM, Li Y, Wu XY. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv. Drug Deliv. Rev. 59, 491-504 (2007). (Pubitemid 47259227)
120. Kuo YC, Su FL. Transport of stavudine, delavirdine, and saquinavir across the blood-brain barrier by polybutylcyanoacrylate, methylmethacrylate- sulfopropylmethacrylate, and solid lipid nanoparticles. Int. J. Pharm. 340, 143-152 (2007).
121. Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. J. Mol. Biol. 13, 238-252 (1965).
122. Lasic D. Liposomes: from Physics to Applications. Elsevier, Amsterdam, The Netherlands (1993).
123. Elorza B, Elorza MA, Sainz MC, Chantres JR. Comparison of particle size and encapsulation parameters of three liposomal preparations. J. Microencapsul. 10, 237-248 (1993). (Pubitemid 23184658)
124. Orthmann A, Zeisig R, Koklic T et al. I. Impact of membrane properties on uptake and transcytosis of colloidal nanocarriers across an epithelial cell barrier model. J. Pharm. Sci. 99, 2423-2433 (2010).
125. Klibanov AL, Maruyama K, Torchilin VP, Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 268, 235-237 (1990). (Pubitemid 20233874)
126. Fritze A, Hens F, Kimpfler A, Schubert R, Peschka-Suss R. Remote loading of doxorubicin into liposomes driven by a transmembrane phosphate gradient. Biochim. Biophys. Acta 1758, 1633-1640 (2006). (Pubitemid 44466698)
127. Li S, Goins B, Phillips WT, Bao A. Remote-loading labeling of liposomes with (99m)Tc-BMEDA and its stability evaluation: effects of lipid formulation and pH/chemical gradient. J. Liposome Res. 21, 17-27 (2011).
128. Joguparthi V, Anderson BD. Liposomal delivery of hydrophobic weak acids: enhancement of drug retention using a high intraliposomal pH. J. Pharm. Sci. 97, 433-454 (2008).
129. Zucker D, Marcus D, Barenholz Y, Goldblum A. Liposome drugs' loading efficiency: a working model based on loading conditions and drug's physicochemical properties. J. Control. Release 139, 73-80 (2009).
130. Pardridge WM. Blood-brain barrier delivery. Drug Discov. Today 12, 54-61 (2007). (Pubitemid 46014479)
131. Pardridge WM. Blood-brain barrier delivery of protein and non-viral gene therapeutics with molecular Trojan horses. J. Control. Release 122, 345-348 (2007). (Pubitemid 47404662)
132. Keller S, Sauer I, Strauss H, Gast K, Dathe M, Bienert M. Membrane-mimetic nanocarriers formed by a dipalmitoylated cell-penetrating peptide. Angew Chem. Int. Ed. Engl. 44, 5252-5255 (2005). (Pubitemid 41223876)
133. Sauer I, Dunay IR, Weisgraber K, Bienert M, Dathe M. An apolipoprotein E-derived peptide mediates uptake of sterically stabilized liposomes into brain capillary endothelial cells. Biochemistry 44, 2021-2029 (2005). (Pubitemid 40223630)
134. Iden DL, Allen TM. In vitro and in vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion approach. Biochim. Biophys. Acta 1513, 207-216 (2001). (Pubitemid 32706418)
135. Pan X, Wu G, Yang W, Barth RF, Tjarks W, Lee RJ. Synthesis of cetuximab-immunoliposomes via a cholesterol-based membrane anchor for targeting of EGFR. Bioconjug. Chem. 18, 101-108 (2007). (Pubitemid 46145999)
136. Steenpass T, Lung A, Schubert R. Tresylated PEG-sterols for coupling of proteins to preformed plain or PEGylated liposomes. Biochim. Biophys. Acta 1758, 20-28 (2006).
137. Pardridge WM. Brain Drug Targeting: the Future of Brain Drug Delivery. Cambridge, UK (2001).
138. Nykjaer A, Willnow TE. The low-density lipoprotein receptor gene family: a cellular Swiss army knife? Trends Cell Biol. 12, 273-280 (2002). (Pubitemid 34634176)
139. Bertrand Y, Currie JC, Demeule M et al. Transport characteristics of a novel peptide platform for CNS therapeutics. J. Cell Mol. Med. 14, 2827-2839 (2010).
140. Tian W, Ying X, Du J et al. Enhanced efficacy of functionalized epirubicin liposomes in treating brain glioma-bearing rats. Eur. J. Pharm. Sci. 41, 232-243 (2010).
141. Zhang Y, Zhu C, Pardridge WM. Antisense gene therapy of brain cancer with an artificial virus gene delivery system. Mol. Ther. 6, 67-72 (2002). (Pubitemid 36124272)
142. Cerletti A, Drewe J, Fricker G, Eberle AN, Huwyler J. Endocytosis and transcytosis of an immunoliposome-based brain drug delivery system. J. Drug Target. 8, 35-446 (2000).
143. Huwyler J, Wu D, Pardridge WM. Brain drug delivery of small molecules using immunoliposomes. Proc. Natl Acad. Sci. USA 93, 14164-14169 (1996). (Pubitemid 26424263)
144. Omori N, Maruyama K, Jin G et al. Targeting of post-ischemic cerebral endothelium in rat by liposomes bearing polyethylene glycol-coupled transferrin. Neurol. Res. 25, 275-279 (2003). (Pubitemid 36520484)
145. Suresh RJ, Venkateswarlu V, Koning GA. Radioprotective effect of transferrin targeted citicoline liposomes. J. Drug Target. 14, 13-19 (2006).
146. Ying X, Wen H, Yao HJ et al. Pharmacokinetics and tissue distribution of dual-targeting daunorubicin liposomes in mice. Pharmacology 87, 105-114 (2011).
147. Visser CC, Stevanovic S, Voorwinden LH et al. Targeting liposomes with protein drugs to the blood-brain barrier in vitro. Eur. J. Pharm. Sci. 25, 299-305 (2005). (Pubitemid 40725060)
148. Chen H, Tang L, Qin Y et al. Lactoferrin-modified procationic liposomes as a novel drug carrier for brain delivery. Eur. J. Pharm. Sci. 40, 94-102 (2010).
149. McNeeley KM, Karathanasis E, Annapragada AV, Bellamkonda RV. Masking and triggered unmasking of targeting ligands on nanocarriers to improve drug delivery to brain tumors. Biomaterials 30, 3986-3995 (2009).
150. McNeeley KM, Sun Z, Sharfstein ST. Techniques for dual staining of DNA and intracellular immunoglobulins in murine hybridoma cells: applications to cell-cycle analysis of hyperosmotic cultures. Cytotechnology 48, 15-26 (2005). (Pubitemid 41752623)
151. Thöle M, Nobmann S, Huwyler J, Bartmann A, Fricker G. Uptake of cationized albumin coupled liposomes by cultured porcine brain microvessel endothelial cells and intact brain capillaries. J. Drug Target. 10, 337-344 (2002). (Pubitemid 34746315)
152. Migliore MM, Vyas TK, Campbell RB, Amiji MM, Waszczak BL. Brain delivery of proteins by the intranasal route of administration: a comparison of cationic liposomes versus aqueous solution formulations. J. Pharm. Sci. 99, 1745-1761 (2010).
153. Feng B, Tomizawa K, Michiue H et al. Delivery of sodium borocaptate to glioma cells using immunoliposome conjugated with anti-EGFR antibodies by ZZ-His. Biomaterials 30, 1746-1755 (2009).
154. Madhankumar AB, Slagle-Webb B, Wang X et al. Efficacy of interleukin-13 receptor-targeted liposomal doxorubicin in the intracranial brain tumor model. Mol. Cancer Ther. 8, 648-654 (2009).
155. Tamaru M, Akita H, Fujiwara T, Kajimoto K, Harashima H. Leptin-derived peptide, a targeting ligand for mouse brain-derived endothelial cells via macropinocytosis. Biochem. Biophys. Res. Commun. 394, 587-592 (2010).
156. Zhang X, Xie J, Li S, Wang X, Hou X. The study on brain targeting of the amphotericin B liposomes. J. Drug Target. 11, 117-122 (2003). (Pubitemid 36869185)
157. Hartz AM, Bauer B, Fricker G, Miller DS. Rapid modulation of P-glycoprotein-mediated transport at the blood-brain barrier by tumor necrosis factor-a and lipopolysaccharide. Mol. Pharmacol. 69, 462-470 (2006). (Pubitemid 43121943)
158. Du J, Lu WL, Ying X et al. Dual-targeting topotecan liposomes modified with tamoxifen and wheat germ agglutinin significantly improve drug transport across the blood-brain barrier and survival of brain tumor-bearing animals. Mol. Pharmacol. 6, 905-917 (2009).
159. Qin Y, Fan W, Chen H et al. In vitro and in vivo investigation of glucose-mediated brain-targeting liposomes. J. Drug Target. 18, 536-549 (2010).
160. Globocan 2008 www.globocan.iarc.fr
161. Oncology channel www.oncologychannel.com/braincancer/index.shtml
162. Merck KGaA Darmstadt, 2010 www.merck.de .